Evidence map›Paper›PMID 40921497›Full record

Trial reportBritish journal of haematology2026

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study.

Ken Ishiyama, Masahide Yamazaki, Hiroyuki Maruyama, Naoko Hosono, Hiroki Yamaguchi, Noboru Asada, Kazuki Tanimoto, Hiroyuki Sugiura, Kensuke Usuki, Kenichi Yoshimura and 5 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ken IshiyamaDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.ORCID https://orcid.org/0000-0002-6189-0620
Masahide YamazakiDepartment of Internal Medicine, Keiju Medical Center, Nanao, Ishikawa, Japan.
Hiroyuki MaruyamaDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Naoko HosonoDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.ORCID https://orcid.org/0000-0002-6336-3250
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Noboru AsadaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0001-7322-5460
Kazuki TanimotoDepartment of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Hiroyuki SugiuraDepartment of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Kenichi YoshimuraDepartment of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University, Nagoya, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
Yuzuru KanakuraSumitomo Hospital, Osaka, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Shinji NakaoDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.ORCID https://orcid.org/0000-0002-9674-624X

Funding

Clinical Research Support Center Kyushu
6 · The paper itself

Abstract

The efficacy of ciclosporin (CsA) to treat transfusion-independent non-severe aplastic anaemia (TI-NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI-NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI-NSAA aged ≥16. The CsA dose was adjusted to maintain a blood CsA level of ≥600 ng/mL at 2 h post-administration. Blood cell counts were assessed after 8, 16 and 52 weeks of therapy. Thirty-two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16-83) years. At 8 weeks, haematological improvement, with increases in haemoglobin (Hb) ≥1.5 g/dL (haematological improvement in erythrocytes [HI-E]) and platelet count ≥30 × 10

Indexed as

Anemia, AplasticCyclosporineImmunosuppressive AgentsAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeYoung AdultCyclosporineImmunosuppressive Agentsciclosporinprospective studyrenal toxicitytransfusion‐independent non‐severe aplastic anaemia

Identifiers

PMID40921497
PMCPMC12819092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.